Schreck KC - Search Results

1

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF^V600E-Mutant Human Glioma.

Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, Green AL, Jones C, Jones KL, Kilburn LB, Nazemi KJ, Samuel D, Sanford B, Solomon DA, Wang J, Pratilas CA, Nicolaides T, Mulcahy Levy JM. Schreck KC, et al. Clin Cancer Res. 2021 Nov 15;27(22):6197-6208. doi: 10.1158/1078-0432.CCR-21-2660. Epub 2021 Aug 25. Clin Cancer Res. 2021. PMID: 34433654 Free PMC article.

2

The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance.

Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG. Schreck KC, et al. Clin Cancer Res. 2010 Dec 15;16(24):6060-70. doi: 10.1158/1078-0432.CCR-10-1624. Clin Cancer Res. 2010. PMID: 21169257 Free PMC article.

3

Notch signaling promotes growth and invasion in uveal melanoma.

Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW, Eberhart CG. Asnaghi L, et al. Among authors: schreck kc. Clin Cancer Res. 2012 Feb 1;18(3):654-65. doi: 10.1158/1078-0432.CCR-11-1406. Epub 2012 Jan 6. Clin Cancer Res. 2012. PMID: 22228632 Free PMC article.

4

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.

Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA. Schreck KC, et al. J Natl Compr Canc Netw. 2018 Apr;16(4):343-347. doi: 10.6004/jnccn.2017.7052. J Natl Compr Canc Netw. 2018. PMID: 29632053

5

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

Schreck KC, Grossman SA, Pratilas CA. Schreck KC, et al. Cancers (Basel). 2019 Aug 28;11(9):1262. doi: 10.3390/cancers11091262. Cancers (Basel). 2019. PMID: 31466300 Free PMC article. Review.

6

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma.

Schreck KC, Allen AN, Wang J, Pratilas CA. Schreck KC, et al. Neurooncol Adv. 2020 Oct 15;2(1):vdaa138. doi: 10.1093/noajnl/vdaa138. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33235998 Free PMC article.

7

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.

Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA. Odeniyide P, et al. Among authors: schreck kc. Oncogene. 2022 May;41(21):2973-2983. doi: 10.1038/s41388-022-02305-x. Epub 2022 Apr 22. Oncogene. 2022. PMID: 35459782 Free PMC article.

8

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.

Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA. Odeniyide P, et al. Among authors: schreck kc. Oncogene. 2022 May;41(21):3037. doi: 10.1038/s41388-022-02342-6. Oncogene. 2022. PMID: 35534540 Free PMC article. No abstract available.

9

Integrated molecular and clinical analysis of BRAF-mutant glioma in adults.

Schreck KC, Langat P, Bhave VM, Li T, Woodward E, Pratilas CA, Eberhart CG, Bi WL. Schreck KC, et al. NPJ Precis Oncol. 2023 Feb 28;7(1):23. doi: 10.1038/s41698-023-00359-y. NPJ Precis Oncol. 2023. PMID: 36854806 Free PMC article.

10

Druggable genomic landscapes of high-grade gliomas.

Ghanem P, Fatteh M, Kamson DO, Balan A, Chang M, Tao J, Blakeley J; Johns Hopkins Molecular Tumor Board Investigators; Canzoniero J, Grossman SA, Marrone K, Schreck KC, Anagnostou V. Ghanem P, et al. Among authors: schreck kc. Front Med (Lausanne). 2023 Dec 8;10:1254955. doi: 10.3389/fmed.2023.1254955. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38143440 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page